(Q24202141)

9

0 references

Andrea Cipriani

1

0 references

Rachel Churchill

7

0 references

Toshi A Furukawa

3

Toshi A Furukawa

0 references

Alessandra Signoretti

6

Alessandra Signoretti

0 references

Norio Watanabe

8

Norio Watanabe

0 references

Giuseppe Imperadore

5

Giuseppe Imperadore

0 references

Marianna Purgato

2

Marianna Purgato

0 references

Carlotta Trespidi

4

Cochrane Database of Systematic Reviews

Carlotta Trespidi

0 references

language of work or name

English

0 references

publication date

2012

0 references

11 July 2012

0 references

published in

0 references

volume

7

0 references

page(s)

CD006534

0 references

cites work

Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Fluvoxamine versus other anti-depressive agents for depression

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Milnacipran versus other antidepressive agents for depression

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Escitalopram versus other antidepressive agents for depression

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Venlafaxine for major depression

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Fluoxetine versus other types of pharmacotherapy for depression

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Why most published research findings are false

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

A rating scale for depression

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Pharmaceutical industry sponsorship and research outcome and quality: systematic review

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Sertraline versus other antidepressive agents for depression

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

St John's wort for major depression

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Antidepressants for depressed elderly

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Measuring inconsistency in meta-analyses

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

The MOS 36-ltem Short-Form Health Survey (SF-36)

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Differences in efficacy and safety of pharmaceutical treatments between men and women: an umbrella review

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Does comorbid substance use disorder impair recovery from major depression with SSRI treatment? An analysis of the STAR*D level one treatment outcomes

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Imputing missing standard deviations in meta-analyses can provide accurate results

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Meta-analyses involving cross-over trials: methodological issues

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Detecting skewness from summary information

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Improving the quality of reporting of randomized controlled trials. The CONSORT statement

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

A New Depression Scale Designed to be Sensitive to Change

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Establishing moderators and biosignatures of antidepressant response in clinical care (EMBARC): Rationale and design

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysis

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Remission with venlafaxine extended release or selective serotonin reuptake inhibitors in depressed patients: a randomized, open-label study

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Why it is important to include unpublished data in systematic reviews.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

What are evidence-based treatment recommendations?

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

The treatment of minor depression with St. John's Wort or citalopram: failure to show benefit over placebo

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Duration of response after treatment of mild to moderate depression with Hypericum extract STW 3-VI, citalopram and placebo: a reanalysis of data from a controlled clinical trial

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Treatment of depressive symptoms in Parkinson's disease

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

The relationship between the acute cerebral metabolic response to citalopram and chronic citalopram treatment outcome

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Escitalopram Versus Citalopram and Sertraline: A Double-Blind Controlled, Multi-centric Trial in Indian Patients with Unipolar Major Depression.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Antidepressant monotherapy vs sequential pharmacotherapy and mindfulness-based cognitive therapy, or placebo, for relapse prophylaxis in recurrent depression

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Can we really accelerate and enhance the selective serotonin reuptake inhibitor antidepressant effect? A randomized clinical trial and a meta-analysis of pindolol in nonresistant depression.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Citalopram reduces endotoxin-induced fatigue

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

A pooled analysis of two randomised, placebo-controlled studies of extended release quetiapine fumarate adjunctive to antidepressant therapy in patients with major depressive disorder

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Prophylactic antidepressant treatment in patients with hepatitis C on antiviral therapy: a double-blind, placebo-controlled trial

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Treatment of subsyndromal depressive symptoms in middle-age and older patients with schizophrenia: effect of age on response

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Home-delivered problem adaptation therapy (PATH) for depressed, cognitively impaired, disabled elders: A preliminary study

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Escitalopram: in the treatment of major depressive disorder in adolescent patients

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

A randomized controlled trial of antidepressant continuation for major depression following traumatic brain injury

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Radio electric treatment vs. Es-Citalopram in the treatment of panic disorders associated with major depression: an open-label, naturalistic study

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Association of mu-opioid receptor variants and response to citalopram treatment in major depressive disorder

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Escitalopram--translating molecular properties into clinical benefit: reviewing the evidence in major depression

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Improving depression and enhancing resilience in family dementia caregivers: a pilot randomized placebo-controlled trial of escitalopram

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Antidepressant medication and executive dysfunction: a deleterious interaction in late-life depression

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

The B-VITAGE trial: a randomized trial of homocysteine lowering treatment of depression in later life

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Diminished neural processing of aversive and rewarding stimuli during selective serotonin reuptake inhibitor treatment

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Change in cognitive functioning following acute antidepressant treatment in late-life depression

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Comparative effectiveness of biomarkers and clinical indicators for predicting outcomes of SSRI treatment in Major Depressive Disorder: results of the BRITE-MD study

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Citalopram for continuation therapy after repetitive transcranial magnetic stimulation in vascular depression

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

The self-reported Montgomery-Asberg Depression Rating Scale is a useful evaluative tool in Major Depressive Disorder

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

The Indiana Cancer Pain and Depression (INCPAD) trial Design of a telecare management intervention for cancer-related symptoms and baseline characteristics of study participants

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Response to a selective serotonin reuptake inhibitor (citalopram) in major depressive disorder with melancholic features: a STAR*D report

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Treatment of alcohol dependence in patients with co-morbid major depressive disorder--predictors for the outcomes with memantine and escitalopram medication

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Does the duration of index episode affect the treatment outcome of major depressive disorder? A STAR*D report

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Sildenafil treatment of women with antidepressant-associated sexual dysfunction: a randomized controlled trial

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

What predicts attrition in second step medication treatments for depression?: a STAR*D Report.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Impact of close family members on older adults' early response to depression treatment

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Brief interpersonal psychotherapy for depressed mothers whose children are receiving psychiatric treatment

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Escitalopram and duloxetine in the treatment of major depressive disorder: a pooled analysis of two trials

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Antidepressants and their onset of action: a major clinical, methodological and pronostical issue

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

GENetic and clinical predictors of treatment response in depression: the GenPod randomised trial protocol

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Acute 5-HT reuptake blockade potentiates human amygdala reactivity.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Escitalopram in the treatment of impulsive-compulsive internet usage disorder: an open-label trial followed by a double-blind discontinuation phase.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

A double blind, placebo-controlled pilot study of galantamine augmentation of antidepressant treatment in older adults with major depression

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Rationale and design of a randomised, controlled, multicenter trial investigating the effects of selective serotonin re-uptake inhibition on morbidity, mortality and mood in depressed heart failure patients (MOOD-HF).

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Remission of maternal depression and child symptoms among single mothers: a STAR*D-Child report.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Effectiveness and acceptability of sertraline and citalopram in major depressive disorder: pragmatic randomized open-label comparison

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Are all antidepressants really the same? The case of fluoxetine: a systematic review.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Comparative efficacy and safety of a once-daily dosage of hypericum extract STW3-VI and citalopram in patients with moderate depression: a double-blind, randomised, multicentre, placebo-controlled study

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

External validity of randomised controlled trials: "to whom do the results of this trial apply?".

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Evaluation of the prophylactic efficacy of amitriptyline and citalopram, alone or in combination, in patients with comorbidity of depression, migraine, and tension-type headache

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Prevalence and outcomes of pharmaceutical industry-sponsored clinical trials involving clozapine, risperidone, or olanzapine.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Are we going to increase the use of antidepressants up to that of benzodiazepines?

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

"Wish bias" in antidepressant drug trials?

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Escitalopram versus citalopram: the surprising role of the R-enantiomer

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Industry sponsorship and authorship of clinical trials over 20 years

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Meta-analysis of effects and side effects of low dosage tricyclic antidepressants in depression: systematic review

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Can we individualize the 'number needed to treat'? An empirical study of summary effect measures in meta-analyses

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Efficacy of intravenous citalopram compared with oral citalopram for severe depression. Safety and efficacy data from a double-blind, double-dummy trial

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Effectiveness of antidepressants. Meta-analysis of dose-effect relationships in randomised clinical trials

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Citalopram and viloxazine in the treatment of depression by means of slow drop infusion. A double-blind comparative trial

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Global assessment of functioning. A modified scale

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Diagnostic Criteria for Use in Psychiatric Research

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

A consumer's guide to subgroup analyses

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Research diagnostic criteria: rationale and reliability

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Olanzapine in the treatment of depression with psychotic features: A prospective open-label study

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Escitalopram versus placebo in the treatment of dysthymic disorder

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Using non-steroidal anti-inflammatory drugs in the treatment of depression.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Genome-wide pharmacogenetics of antidepressant response in the GENDEP project

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Efficacy and tolerability of clomipramine, pirlindole and escitalopram in the treatment of neurotic level depression

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Escitalopram prevents relapse in older patients with major depressive disorder

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

The effect of dermatologic precautions on the incidence of rash with addition of lamotrigine in the treatment of bipolar I disorder: a randomized trial.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Suicide, depression, and antidepressants

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Selective serotonin reuptake inhibitors

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Depression and Alzheimer's disease: symptom or comorbidity?

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

SSRIs do not worsen Parkinson's disease: evidence from an open-label, prospective study.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Health of the Nation Outcome Scales (HoNOS). Research and development

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Efficacy and tolerability of citalopram in comparison with fluvoxamine in depressed outpatients: a double-blind, multicentre study. The LUCIFER Group.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Changes in sleep polygraphic variables and clinical state in depressed patients during treatment with citalopram.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Orthostatic side effects of clomipramine and citalopram during treatment for depression

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Citalopram versus mianserin. A controlled, double-blind trial in depressed patients

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Dexamethasone suppression test and the response to antidepressant depending on their central monoaminergic action in major depression

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Citalopram versus maprotiline: a controlled, clinical multicentre trial in depressed patients.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A Nordic multicentre study.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Efficacy and tolerability of venlafaxine in geriatric outpatients with major depression: a double-blind, randomised 6-month comparative trial with citalopram

30 May 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

Screening and treating depressed patients. A comparison of two controlled citalopram trials across treatment settings: hospitalized patients vs. patients treated by their family doctors. Danish University Antidepressant Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

A double-blind comparison of citalopram (Lu 10-171) and amitriptyline in depressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

A randomised, double-blind comparison of the efficacy and safety of citalopram compared to mianserin in elderly, depressed patients with or without mild to moderate dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

Efficacy and tolerability of reboxetine compared with citalopram: a double-blind study in patients with major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

Polymorphism of the 5-HT transporter and response to antidepressants: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

Oral citalopram and reboxetine challenge tests before and after selective antidepressant treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

Citalopram versus nortriptyline in late-life depression: a 12-week randomized single-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

Efficacy and safety of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, randomized, double-blind, flexible-dose study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

Targeting remission by 8 weeks: when should supplementation be considered in patients with major depression treated with a specific serotonin reuptake inhibitor?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

Short-term intravenous citalopram augmentation in partial/nonresponders with major depression: a randomized placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

Intravenous augmentative citalopram versus clomipramine in partial/nonresponder depressed patients: a short-term, low dose, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

Naltrexone augmentation in OCD: a double-blind placebo-controlled cross-over study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

Safety and efficacy of s-citalopram in patients with co-morbid major depression and diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

Open-label study of s-citalopram therapy of chronic fatigue syndrome and co-morbid major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

An index of 5-HT synthesis changes during early antidepressant treatment: alpha-[11C]methyl-L-tryptophan PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

Normalization of enhanced fear recognition by acute SSRI treatment in subjects with a previous history of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

Baseline anxiety effect on outcome of SSRI treatment in patients with severe depression: escitalopram vs paroxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

Investigating the effectiveness, safety and tolerability of quetiapine in the treatment of anorexia nervosa in young people: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

The relationship between adverse events during selective serotonin reuptake inhibitor treatment for major depressive disorder and nonremission in the suicide assessment methodology study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

The use of referenced-EEG (rEEG) in assisting medication selection for the treatment of depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

Quetiapine augmentation of treatment-resistant depression: a comparison with lithium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

Open-label study of high (30 mg) and moderate (20 mg) dose escitalopram for the treatment of obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

Changes in self-schema structure in cognitive therapy for major depressive disorder: a randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

A double-blind, placebo-controlled treatment trial of citalopram for major depressive disorder in older patients with heart failure: the relevance of the placebo effect and psychological symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

Clinical response augments NK cell activity independent of treatment modality: a randomized double-blind placebo controlled antidepressant trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

Sleep and cognition at baseline and the effects of REM sleep diminution after 1 week of antidepressive treatment in patients with depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

Differential effects of reboxetine and citalopram on hand-motor function in patients suffering from major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

Cost-effectiveness of escitalopram versus citalopram in the treatment of severe depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on memory and mental processing speed in patients with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

Prophylactic effect of citalopram in unipolar, recurrent depression: placebo-controlled study of maintenance therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

Moderation of antidepressant response by the serotonin transporter gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

Superiority of escitalopram to paroxetine in the treatment of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

Antidepressive treatment in patients with temporal lobe epilepsy and major depression: a prospective study with three different antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

Antidepressant use in nonmajor depression: secondary analysis of a program to encourage active, rewarding lives for seniors (PEARLS), a randomized controlled trial in older adults from 2000 to 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

(S)-(+)-mecamylamine (TC-5214): a neuronal nicotinic receptor modulator enters phase III trials as an adjunct treatment for Major Depressive Disorder (MDD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

A pragmatic 12-week, randomized trial of duloxetine versus generic selective serotonin-reuptake inhibitors in the treatment of adult outpatients in a moderate-to-severe depressive episode.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

Relapse prevention by citalopram in SAD patients responding to 1 week of light therapy. A placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

Effects of intravenous antidepressant drugs on the excitability of human motor cortex: a study with paired magnetic stimulation on depressed patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

Effects of erythropoietin on emotional processing biases in patients with major depression: an exploratory fMRI study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

Age at onset of first depressive episode as a predictor for escitalopram treatment of major depression comorbid with alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

Variation in catechol-O-methyltransferase is associated with duloxetine response in a clinical trial for major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

Aripiprazole as adjunct to a mood stabilizer and citalopram in bipolar depression: a randomized placebo-controlled pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

Prediction of the response to citalopram and reboxetine in post-stroke depressed patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

New possibilities of treatment for panic attacks in elderly patients: escitalopram versus citalopram.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

Antidepressant pharmacotherapy in the treatment of depression in the very old: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

MRI subcortical hyperintensities in old and very old depressed outpatients: the important role of age in late-life depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

The 40th anniversary of the National Institute on Alcoholism and Alcohol Abuse: the impact on liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

Safety and efficacy of oral escitalopram as continuation treatment of intravenous citalopram in patients with major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

A randomized double-blind placebo-controlled trial of treatment as usual plus exogenous slow-release melatonin (6 mg) or placebo for sleep disturbance and depressed mood

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

A pragmatic randomised controlled trial to compare antidepressants with a community-based psychosocial intervention for the treatment of women with postnatal depression: the RESPOND trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

Response inhibition predicts poor antidepressant treatment response in very old depressed patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

Escitalopram versus ethinyl estradiol and norethindrone acetate for symptomatic peri- and postmenopausal women: impact on depression, vasomotor symptoms, sleep, and quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

Citalopram versus desipramine in treatment resistant depression: effect of continuation or switching strategies: a randomized open study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

Persistence of antidepressant treatment effects in a pharmacotherapy plus psychotherapy trial for active injection drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

Escitalopram in the long-term treatment of major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

Can phase III trial results of antidepressant medications be generalized to clinical practice? A STAR*D report

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

Subsyndromal depressive symptoms in middle-aged and older persons with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

Augmentation with citalopram for suicidal ideation in middle-aged and older outpatients with schizophrenia and schizoaffective disorder who have subthreshold depressive symptoms: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

Fluoxetine versus other types of pharmacotherapy for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

Sertraline versus other antidepressive agents for depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

Escitalopram versus other anti-depressive agents for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

Citalopram versus other anti-depressive agents for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

Differentiating moderate and severe depression using the Montgomery-Asberg depression rating scale (MADRS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

Milnacipran versus other anti-depressive agents for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

Fluvoxamine versus other anti-depressive agents for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

Symptom profiles of depression among general medical service users compared with specialty mental health service users

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

The citalopram challenge test in patients with major depression and in healthy controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

Response to a Selective Serotonin Reuptake Inhibitor (Citalopram) in Major Depressive Disorder With Melancholic Features

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

Imputing response rates from means and standard deviations in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

The World Health Organization quality of life assessment (WHOQOL): Development and general psychometric properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

Treatment of depression in type 2 diabetes with Fluoxetine or Citalopram?

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Desvenlafaxine and escitalopram for the treatment of postmenopausal women with major depressive disorder

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Platelet serotonin (5-HT) levels in interferon-treated patients with hepatitis C and its possible association with interferon-induced depression

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Why internal and external validity of experimental studies are relevant for clinical practice?

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Differential prediction of first clinical response to serotonergic and noradrenergic antidepressants using the loudness dependence of auditory evoked potentials in patients with major depressive disorder.

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Escitalopram maintenance treatment for prevention of recurrent depression: a randomized, placebo-controlled trial.

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Substance Use Disorder Comorbidity in Major Depressive Disorder: A Confirmatory Analysis of the STAR*D Cohort

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Efficiency and safety of citalopram and venlafaxine in treatment of depressive disorders in elderly patients

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Citalopram versus sertraline in late-life nonmajor clinically significant depression: a 1-year follow-up clinical trial.

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Clinical efficacy of citalopram in patients with hypertension and concomitant depression

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Effect of zinc supplementation on antidepressant therapy in unipolar depression: a preliminary placebo-controlled study.

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Structural and energetic processes related to P300: LORETA findings in depression and effects of antidepressant drugs.

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Abrupt and brief discontinuation of antidepressant treatment: effects on cognitive function and psychomotor performance.

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group.

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

A double-blind multicenter trial comparing sertraline and citalopram in patients with major depression treated in general practice.

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Citalopram and imipramine in the treatment of depressive patients in general practice. A Nordic multicentre clinical study.

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

5HT1A receptors and pharmacotherapy. Is serotonin receptor down-regulation linked to the mechanism of action of antidepressant drugs?

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4204633

Pharmacokinetic consequences of a citalopram treatment discontinuation

29 November 2018

1 reference

12 December 2020

Light treatment of seasonal affective disorder in combination with citalopram or placebo with 1-year follow-up

1 reference

12 December 2020

Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association

1 reference

12 December 2020

Costs and outcomes of use of amitriptyline, citalopram and fluoxetine in major depression: exploratory study

1 reference

12 December 2020

Administration of Citalopram Before ECT: Seizure Duration and Hormone Responses

1 reference

12 December 2020

Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: an analysis of the food and drug administration summary basis of approval reports

1 reference

12 December 2020

Different gender response to serotonergic and noradrenergic antidepressants. A comparative study of the efficacy of citalopram and reboxetine

1 reference

12 December 2020

After the failure of citalopram for depression, what next?

1 reference

12 December 2020

Treatment of depression in patients with coronary artery disease

1 reference

12 December 2020

Evidence-based guidelines for interpretation of the Hamilton Rating Scale for Depression

1 reference

12 December 2020

Comparison of escitalopram versus citalopram for the treatment of major depressive disorder in a geriatric population

1 reference

12 December 2020

TNF-α antagonist infliximab in the treatment of depression in older adults: results of a prematurely ended, randomized, placebo-controlled trial

1 reference

12 December 2020

Prophylactic citalopram treatment in hepatitis C patients on antiviral therapy: Will it limit drug-induced depression and enhance adherence?

1 reference

12 December 2020

Faster onset of antidepressant effects of citalopram compared with sertraline in drug-naïve first-episode major depressive disorder in a Chinese population: a 6-week double-blind, randomized comparative study

1 reference

12 December 2020

[Therapy of moderately severe depressions in daily practice: first patient care research study reinforces clinical data]

1 reference

12 December 2020

Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Danish University Antidepressant Group

1 reference

12 December 2020

The Diagnostic Melancholia Scale (DMS): dimensions of endogenous and reactive depression with relationship to the Newcastle Scales

1 reference

12 December 2020

Plasma tryptophan and tyrosine ratios to competing amino acids in relation to antidepressant response to citalopram and maprotiline. A preliminary study

1 reference

12 December 2020

A comparison of the antidepressant action of citalopram and amitriptyline

1 reference

12 December 2020

The effects of citalopram (Lu 10-171) on the serotonin (5-HT) uptake kinetics in platelets from endogenously depressed patients

1 reference

12 December 2020

Clinical and biochemical effects of citalopram, a selective 5-HT reuptake inhibitor--a dose-response study in depressed patients

1 reference

12 December 2020

[Citalopram and desmethylcitalopram for psychiatric patients]

1 reference

12 December 2020

Citalopram versus fluoxetine: a double-blind, controlled, multicentre, phase III trial in patients with unipolar major depression treated in general practice

1 reference

12 December 2020

A double-blind double-dummy study of citalopram comparing infusion versus oral administration

1 reference

12 December 2020

Comparison of the tolerability and efficacy of citalopram and amitriptyline in elderly depressed patients treated in general practice

1 reference

12 December 2020

A Comparison of Mirtazapine and Nortriptyline Following Two Consecutive Failed Medication Treatments for Depressed Outpatients: A STAR*D Report

1 reference

12 December 2020

Does the Duration of Index Episode Affect the Treatment Outcome of Major Depressive Disorder?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006534.PUB2

7 January 2021